Your browser doesn't support javascript.
loading
First-in-Class Combination Therapy of a Copper(II) Metallo-Phosphorus Dendrimer with Cytotoxic Agents.
Mignani, Serge; El Brahmi, Nabil; Cresteil, Thierry; Majoral, Jean-Pierre.
Afiliação
  • Mignani S; Laboratoire de Chimie et de Biochimie pharmacologiques et toxicologique, CNRS UMR 860, Université Paris Descartes, PRES Sorbonne Paris Cité, Paris, France.
  • El Brahmi N; CQM Centro de Química da Madeira, MMRG, Universidade da Madeira, Funchal, Portugal.
  • Cresteil T; Euromed Research Institute, Engineering Division, Euro-Mediterranean University of Fes, Fès, Morocco.
  • Majoral JP; IPSIT Faculté de Pharmacie, Université Paris Sud, Châtenay-Malabry, France.
Oncology ; 94(5): 324-328, 2018.
Article em En | MEDLINE | ID: mdl-29533961
ABSTRACT
The metallo-phosphorus dendrimer 1G3-Cu (generation 3 dendrimer bearing 48 conjugated copper(II) on its surface) has antiproliferative activity related to its capacity to activate Bax translocation. In the present study, we evaluate the activity of an association of 1G3-Cu with 5 cytotoxic agents used in chemotherapy having different modes of action. Data show no additive effect with camptothecin and cisplatin, additivity with paclitaxel and MG132, and synergy with doxorubicin. Results suggest that the multivalent Cu-conjugated dendrimer 1G3-Cu (activator of Bax translocation) plays an important role in boosting the clinical impact of Bax accumulation stimulated by the proteasome inhibitor MG132, antimitotic taxanes, and the topo II inhibitor doxorubicin.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transporte Biológico Ativo / Células Tumorais Cultivadas / Citotoxinas / Linhagem Celular Tumoral / Antineoplásicos Limite: Humans Idioma: En Revista: Oncology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transporte Biológico Ativo / Células Tumorais Cultivadas / Citotoxinas / Linhagem Celular Tumoral / Antineoplásicos Limite: Humans Idioma: En Revista: Oncology Ano de publicação: 2018 Tipo de documento: Article País de afiliação: França